Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Benchmark Holdings Plc LSE:BMK London Ordinary Share GB00BGHPT808 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 37.45 811 09:00:08
Bid Price Offer Price High Price Low Price Open Price
37.00 38.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 125.06 -9.18 -1.93 264
Last Trade Time Trade Type Trade Size Trade Price Currency
11:45:14 O 529 37.95 GBX

Benchmark (BMK) Latest News

More Benchmark News
Benchmark Investors    Benchmark Takeover Rumours

Benchmark (BMK) Discussions and Chat

Benchmark Forums and Chat

Date Time Title Posts
07/12/202216:03Benchmark Holdings Plc480
19/5/202107:35SALMON prices 30 year high and CAT VACCINES are Go-Go566

Add a New Thread

Benchmark (BMK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
11:45:1637.95529200.76O
11:18:5037.95269.87O
10:52:4137.056925.56O
10:02:2837.0518769.28O
2023-02-06 16:29:1537.506925.88AT
View all Benchmark trades in real-time

Benchmark (BMK) Top Chat Posts

Top Posts
Posted at 07/2/2023 08:20 by Benchmark Daily Update
Benchmark Holdings Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker BMK. The last closing price for Benchmark was 37.45p.
Benchmark Holdings Plc has a 4 week average price of 37p and a 12 week average price of 35.50p.
The 1 year high share price is 57p while the 1 year low share price is currently 35p.
There are currently 703,960,798 shares in issue and the average daily traded volume is 647,394 shares. The market capitalisation of Benchmark Holdings Plc is £263,633,318.85.
Posted at 07/12/2022 16:03 by edmonda
New research note & audio summary ("FY22 results deliver sustainable growth")

Full report here (free & accessible here): https://www.equitydevelopment.co.uk/research/fy22-results-deliver-sustainable-growth

For the year to 30 September 2022, Benchmark Holdings reported revenue of £158.3m, +27%YoY and (adj.) EBITDA of £31.2m, +60%YoY. The Group highlighted 14%YoY growth in the Advanced Nutrition business area, as shrimp market demand continues to recover, and 24%YoY growth in Genetics as the new Iceland salmon eggs facility came on stream. FY22 EBITDA (adj.) was in line with the upper end of the Trading Update of 24 October; revenue was 3% above our October estimates, EBITDA (adj.) 14% higher. EBITDA (adj.) margin improved from 15.6% in FY21 to 19.7%, maintaining progress from 13.7% in FY20. Following FY22 performance which matched updated guidance – reiterating Benchmark’s ‘delivery’ strategy - our FY23 and FY24 outlook is essentially unchanged, with top line and EBITDA growth maintained; LBT is reduced as a result of debt restructuring undertaken in November 2022. Our outlook equates to a FY24 EV/EBITDA of 9.1x, and Fair Value is still seen at 63p/share.

Posted at 27/10/2022 10:06 by murdo mcsponge
I believe they have loads of stock. That's another reason why the price should be higher. It all points to moving onto the Oslo Exchange, where they actually understand what Aquaculture and its Risk Management is all about. IMHO this is an excellent Company which is extremely well positioned in one of the few industry sectors that is expanding. Just my personal opinion. Everyone should do their own research. I may have got it completely wrong!
Posted at 25/10/2022 15:59 by murdo mcsponge
What a nonsense. Some excellent figures and the stock price drops.
Posted at 25/10/2022 07:04 by edmonda
That was a positive update on a strong Q4 and BMK now sees FY22 adj EBITDA beating market expectations.

Equity Development's fair value for now stays at 63p/share, vs 37p in the market, as you can read in new research note here (free access):

https://www.equitydevelopment.co.uk/research/update-says-a-strong-q4-continuing-into-fy23

Posted at 12/10/2022 08:06 by edmonda
Benchmark Holdings - "Sustainable growth through consistent delivery" - major new research report (free & accessible) from Equity Development; CMD and Business Review

Link to full note and audio summary:
https://www.equitydevelopment.co.uk/research/sustainable-growth-through-consistent-delivery

At the recent Capital Markets Day CEO Trond Williksen outlined Benchmark’s strategy: to drive sustainability in aquaculture, improving product yield and quality for its customers, and at the same time to build Benchmark’s growth through planned phases of development in its three key business areas - Genetics, Advanced Nutrition and Health.

Restructured in 2020, the Group is now focused on consistent delivery, anchoring business area profitability and cashflow, and delivering on strategic programmes within a 2-5-year time frame. The direction of travel for Benchmark’s target markets in aquaculture remains positive. As the OECD1 notes “fish consumption is projected to keep rising at a faster rate than meat consumption over the next decade” and “Aquaculture is expected to drive production growth …to overtake capture fisheries production.” The Group outlined its growth pathway for each business area.

Our fair value for Benchmark is 63p/share.

Posted at 05/9/2022 08:35 by edmonda
Q3 update: Positive outlook in uncertain times

See full details in our new note: https://www.equitydevelopment.co.uk/research/q3-update-positive-outlook-in-uncertain-times

Summary

Benchmark’s results for the FY22 Q3 (April-June) period showed robust sales plus adjusted EBITDA (AEBITDA) growth and confirm a positive outlook, particularly in the important genetics and advanced nutrition businesses. Medium-term financial guidance, issued only in May, was reiterated, something that represents a positive element in the investment case given current heightened economic uncertainty. Benchmark’s status as a key player in the global aquaculture industry should be a defensive attribute and it also confirms low exposure to spiking utility costs - an additional attractive feature in the present energy crisis.

We recently revised our valuation principally to reflect the changed macro-economic (inflation/interest rate) environment and, while this has deteriorated further since this was carried out in June, we do not consider there is yet a need to change the valuation.

Thus, we are maintaining the current valuation of £478m (or 68p/share), which is struck on the basis of a 12% weighted average cost of capital and 3% long term growth rate.

Posted at 08/8/2022 15:26 by murdo mcsponge
Why the sudden price drop? Does somebody know something that the rest of us don't?
Posted at 09/6/2022 14:44 by edmonda
New research report (free access): "Financial update highlights strong outlook"

Benchmark reported a fourth sequential quarter of revenue and AEBITDA profit growth in the January-March (Q2) period, highlighting the continued favourable trends in its three business areas. The group has, so far, been largely unaffected by the post February economic shock and maintains that it continues to have a strong outlook in its important salmon egg and nutrition businesses for the remainder of the year.

Key points to note include:

Q2 results: revenues were up by 29% at £39.3m, reflecting strong growth in the three divisions of Nutrition (+16%), Genetics (+20%) and Health (+390%). These were broadly consistent with or ahead of our expectations.

Safe haven status: Benchmark’s alignment to the aquaculture segment should mean it is largely insulated from economic disruption caused by the Russian invasion of Ukraine and associated sanctions.

Balance sheet: Benchmark has a strong balance sheet with cash of £46.2m and net debt of £81.4m on 31st March, which is a positive element in the investment case. We expect the company will look to refinance its NOK855m bond in the second half of 2022.

We have also revised our DCF-valuation to reflect forecasts and now assume a higher cost of capital more appropriate to the current inflation/interest rate environment. Our model yields a fair valuation of £478m or 68p/share, versus the current 51p level.

Link to full research report: https://www.equitydevelopment.co.uk/research/financial-update-highlights-strong-outlook

Posted at 23/3/2022 20:51 by hedgehog 100
It's interesting to note BMK's strong cash position:
"Cash of £50.6m and Liquidity (cash and available facility) of £61.6m as at 21 February 2022"

Considering the buy-&-build strategy employed by BMK, then OTAQ, which has BMK founder Malcolm Pye as a director, could be a potential BMK takeover target.

In fact, at its current share price of just 20.5p OTAQ looks a sitting duck for a BMK takeover attempt, and looks a prefect fit.

Thought I think that it would have to pay at least double or treble OTAQ's current share price to succeed.


"Malcolm Pye
Non Executive Director
Malcolm founded, and from 1999 to 2019 was Chief Executive of, Benchmark Holdings plc ("Benchmark"), the world's leading aquaculture health, nutrition and genetics business. Malcolm has over 35 years' experience in international agribusiness through his various roles at Hillsdown Holdings (then HMTF Group), and through building Benchmark from the initial start-up into a major international aquaculture technology business serving the global salmon, shrimp, tilapia and farmed fish industries. Malcolm focused Benchmark's activities on animal health, breeding and genetics, advanced nutrition and knowledge/technology delivery and led the flotation of Benchmark in 2013, maintaining a lead role in investor engagement."
HTTP://www.otaq-ir.com/investors/board-of-directors

Posted at 14/2/2022 12:50 by km18
...from a while ago ...

Benchmark Holdings issued a trading update earlier in the week. There is continued good momentum across all business areas, FY21 results are expected to be significantly ahead of market expectations. The Group's Adjusted EBITDA for FY21 is expected to be significantly ahead of the current market consensus which is £15.9m. This suggests that the company could even post positive EPS in FY21 for the first time in 7 years. But valuation is not particularly attractive, PS ratio of near 4 is bottom half for the Pharmaceuticals sector. The company ran at a loss for 7 years in a row between FY14 and FY20, there is no rush to buy here. But BMK is quite an interesting company and perhaps a share to monitor for now....from WealthOracleAM

https://wealthoracle.co.uk/detailed-result-full/BMK/216

Benchmark share price data is direct from the London Stock Exchange
Your Recent History
LSE
BMK
Benchmark
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20230207 14:21:02